{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T04:48:01Z","timestamp":1780462081451,"version":"3.54.1"},"reference-count":21,"publisher":"Public Library of Science (PLoS)","issue":"6","license":[{"start":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T00:00:00Z","timestamp":1750723200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010621","name":"Uniwersytet Medyczny w Lublinie","doi-asserted-by":"publisher","award":["DS176"],"award-info":[{"award-number":["DS176"]}],"id":[{"id":"10.13039\/501100010621","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Acute myeloid leukemia (AML) is associated with the accumulation of acquired genetic disorders. Moreorver chromosomal and molecular changes are independent prognostic factors that are taken into account to determine prognosis and treatment. MicroRNAs are novel gene regulators, which have been recognized to play an important role in pathological leukemogenesis. This study is aimed to analyze the possible role of micro RNAs as a markers predicting the outcome to induction chemotherapy based on cytarabine.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Materials and methods<\/jats:title>\n<jats:p>The expression of miR-34a, miR-191, miR-199a and miR-199b in previously separated bone marrow cells was assessed at the moment of diagnosis in 44 AML patients with use of qRQ-PCR technique. Assessment of response to induction therapy was based on criteria for response to treatment proposed by European LeukemiaNet (ELN).<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>Only the expression level of miR-191a out of all analyzed microRNAs was significantly associated with the induction chemotherapy response. We detected also significantly higher expression of miR-191 in <jats:italic>FLT3-ITD<\/jats:italic> negative group in comparison to <jats:italic>FLT3-ITD<\/jats:italic> positive subjects. For miR-34a, miR-199a and miR-199b, no relationship was found between their expression and <jats:italic>FLT3-ITD<\/jats:italic>, <jats:italic>NPM1<\/jats:italic> and <jats:italic>CEBPA<\/jats:italic> mutations. It was also shown that in the group of patients with low miR-191 expression, the number of myeloblasts was higher (p\u2009&lt;\u20090.05).<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>These results may prove an important role of miR-191a expression as a predictor of response to the induction chemotherapy based on cytarabine, even in cases when other risk factors are absent.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0324320","type":"journal-article","created":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T17:44:21Z","timestamp":1750787061000},"page":"e0324320","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":1,"title":["Pretreatment expression of miR-191a may predict response to the induction chemotherapy based on cytarabine in acute myeloid leukemia patients \u2013 a single-center pilotal study"],"prefix":"10.1371","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8347-7557","authenticated-orcid":true,"given":"Agnieszka","family":"Szymczyk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylwia","family":"Chocholska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarzyna","family":"Radko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marek","family":"Hus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Podhorecka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2025,6,24]]},"reference":[{"issue":"7","key":"pone.0324320.ref001","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2016.50","article-title":"Acute myeloid leukemia: a comprehensive review and 2016 update","volume":"6","author":"I De Kouchkovsky","year":"2016","journal-title":"Blood Cancer J"},{"key":"pone.0324320.ref002","article-title":"Incidence and Mortality Patterns of Acute Myeloid Leukemia in Belgrade, Serbia (1999\u20132013)","volume":"54","author":"N Maksimovic","year":"2018","journal-title":"Medicina (Kaunas)"},{"issue":"1","key":"pone.0324320.ref003","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1745-6673-8-14","article-title":"Work-related leukemia: a systematic review","volume":"8","author":"I Polychronakis","year":"2013","journal-title":"J Occup Med Toxicol"},{"issue":"20","key":"pone.0324320.ref004","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"DA Arber","year":"2016","journal-title":"Blood"},{"issue":"2","key":"pone.0324320.ref005","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S0268-960X(03)00040-7","article-title":"Cytogenetics in acute leukemia","volume":"18","author":"K Mr\u00f3zek","year":"2004","journal-title":"Blood Rev"},{"key":"pone.0324320.ref006","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1053\/j.seminoncol.2008.04.007","article-title":"Acute myeloid leukemia with a complex karyotype","volume":"35","author":"K Mr\u00f3zek","year":"2008","journal-title":"Semin Oncol"},{"issue":"12","key":"pone.0324320.ref007","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 ELN recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"H D\u00f6hner","year":"2022","journal-title":"Blood"},{"issue":"10","key":"pone.0324320.ref008","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0164587","article-title":"Value of Different Comorbidity Indices for Predicting Outcome in Patients with Acute Myeloid Leukemia","volume":"11","author":"M Wass","year":"2016","journal-title":"PLoS One"},{"issue":"1","key":"pone.0324320.ref009","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s12943-016-0518-2","article-title":"Clinical significance of microRNAs in chronic and acute human leukemia","volume":"15","author":"C-H Yeh","year":"2016","journal-title":"Mol Cancer"},{"issue":"12","key":"pone.0324320.ref010","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/gm516","article-title":"MicroRNAs and the cancer phenotype: profiling, signatures and clinical implications","volume":"5","author":"C Stahlhut","year":"2013","journal-title":"Genome Med"},{"key":"pone.0324320.ref011","doi-asserted-by":"crossref","first-page":"255","DOI":"10.3389\/fonc.2017.00255","article-title":"microRNAs and Acute Myeloid Leukemia Chemoresistance: A Mechanistic Overview","volume":"7","author":"MM Gabra","year":"2017","journal-title":"Front Oncol"},{"key":"pone.0324320.ref012","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.clml.2019.08.007","article-title":"Impact of time between induction chemotherapy and complete remission on survival outcomes in patients with acute myeloid leukemia","volume":"19","author":"R Ciftciler","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"pone.0324320.ref013","first-page":"324","article-title":"MicroRNA-mRNA Pairs Associated with outcome in AML: From in vitro cell-based studies to AML patients","volume":"6","author":"NS Bhise","year":"2015","journal-title":"Front Pharmacol"},{"issue":"6","key":"pone.0324320.ref014","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1124\/dmd.114.062844","article-title":"Inflammation-associated microRNA-130b down-regulates cytochrome P450 activities and directly targets CYP2C9","volume":"43","author":"JK Rieger","year":"2015","journal-title":"Drug Metab Dispos"},{"issue":"7439","key":"pone.0324320.ref015","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/nature11919","article-title":"MicroRNA-34a regulates cardiac ageing and function","volume":"495","author":"RA Boon","year":"2013","journal-title":"Nature"},{"key":"pone.0324320.ref016","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/1746-1596-9-76","article-title":"Prognostic value of miR-96 in patients with acute myeloid leukemia","volume":"9","author":"J Zhao","year":"2014","journal-title":"Diagn Pathol"},{"issue":"24","key":"pone.0324320.ref017","first-page":"4841","article-title":"Overexpressed miR-155 is associated with initial presentation and poor outcome in Chinese pediatric acute myeloid leukemia","volume":"19","author":"L-H Xu","year":"2015","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"pone.0324320.ref018","article-title":"Diagnostic value of mir-34a in bone marrow mononuclear cells of acute myeloid leukemia patients","volume":"66","author":"X Liu","year":"2020","journal-title":"Clin Lab"},{"issue":"4","key":"pone.0324320.ref019","doi-asserted-by":"crossref","first-page":"319","DOI":"10.3390\/genes10040319","article-title":"MicroRNAs Mediated Regulation of Expression of Nucleoside Analog Pathway Genes in Acute Myeloid Leukemia","volume":"10","author":"NS Bhise","year":"2019","journal-title":"Genes (Basel)"},{"key":"pone.0324320.ref020","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s40164-016-0033-6","article-title":"miR-199b, a novel tumor suppressor miRNA in acute myeloid leukemia with prognostic implications","volume":"5","author":"AJ Favreau","year":"2016","journal-title":"Exp Hematol Oncol"},{"issue":"6","key":"pone.0324320.ref021","doi-asserted-by":"crossref","first-page":"3183","DOI":"10.1182\/blood-2007-07-098749","article-title":"MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia","volume":"111","author":"R Garzon","year":"2008","journal-title":"Blood"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0324320","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T17:44:29Z","timestamp":1750787069000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0324320"}},"subtitle":[],"editor":[{"given":"Francesco","family":"Bertolini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,6,24]]},"references-count":21,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,6,24]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0324320","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,24]]}}}